Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 20/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.39 |
| ▸ | VHL | P40337 | 1/20 | 0.37 |
| ▸ | CDK7 | P50613 | 1/20 | 0.37 |
| ▸ | CCNH | P51946 | 1/20 | 0.37 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19636820 | 1.00 | KRAS (0.43) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL31344938 | 1.00 | KRAS (0.43) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL21962829 | 0.92 | KRAS (0.45) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL21319823 | 0.91 | KRAS (0.45) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL31344907 | 0.91 | KRAS (0.45) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL21315090 | 0.87 | KRAS (0.42) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL21315087 | 0.87 | KRAS (0.42) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL19637243 | 0.85 | KRAS (0.39) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL19617279 | 0.84 | KRAS (0.56) | KRASSOS1VHLCDK7CCNH | |
| SCHEMBL19616467 | 0.84 | KRAS (0.56) | KRASSOS1VHLCDK7CCNH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308170-A1 | KRAS G12C INHIBITORS | ARRAY BIOPHARMA INC. | 2020-10-01 | — | — | US | disclosed |
| WO-2020101736-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-10647715-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190270743-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647715-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 94/4885VHL 4/4885 |
| US-20200308170-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 94/4885VHL 4/4885 |
| US-20190270743-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | KRAS 1/4885SOS1 94/4885VHL 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.